PVD Treatment Medical Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for PVD Treatment Medical Devices
1.1 - About PVD Treatment Medical Devices sector
Companies in the PVD Treatment Medical Devices category design and manufacture endovascular tools for treating peripheral arterial and venous disease. They deliver minimally invasive solutions that enable revascularization, plaque modification, and thrombus removal, helping providers expand therapy options and standardize care pathways. The focus is on reliable device performance, broad procedural coverage, and integration with cath lab workflows.
Typical portfolios include PTA angioplasty balloons and drug-coated balloons that dilate vessels while delivering antiproliferative therapy, as well as self-expanding peripheral stents for scaffold support. Vendors offer atherectomy systems and intravascular lithotripsy to modify plaque and calcium, plus thrombectomy catheters and embolic protection to manage clot and debris. Strategic buyers often pair these with guidewires, crossing catheters, sheaths, and closure accessories to enable complete endovascular procedures.
Primary customers include hospital cath labs and vascular service lines, ambulatory surgery centers, and interventional radiology and cardiology departments. These companies enable faster case throughput, lower device and procedure costs through standardized kits, improved clinical outcomes that support reimbursement, and reduced supply chain complexity via integrated portfolios. Buyers also gain coverage across lesion types and anatomies, supporting expansion of peripheral intervention programs.
2. Buyers in the PVD Treatment Medical Devices sector
2.1 Top strategic acquirers of PVD Treatment Medical Devices companies
Tactile Medical
HQ: United States
Website
- Description: Provider of advanced at-home pneumatic compression and therapy devices, including the Flexitouch system and supportive mobile tools, that treat lymphedema, chronic venous insufficiency, chronic swelling and venous ulcers, enabling patients to manage symptoms and improve quality of life.
- Key Products:
- Flexitouch Plus: Pneumatic compression device delivering programmed pressure cycles to reduce head-and-neck cancer lymphedema
- easy to prescribe and enables patients to self-manage swelling at home
- Nimbl: Lightweight, compact pneumatic compression unit that lets patients independently manage lymphedema and chronic swelling, providing convenient daily therapy without bulky equipment
- Kylee App: Mobile application allowing individuals with chronic venous insufficiency to track progress of at-home therapy, offering real-time insight and encouraging treatment adherence
- On-demand Continuing Education Courses: Web-based modules such as “Pelvic Cancer Diagnosis
- Treatment, and Related Lymphedema” that award complimentary contact hours and equip clinicians with practical guidance to enhance patient outcomes.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PVD Treatment Medical Devices sector
M&A buyer group 1: Diversified Medical Devices
27 companies
View group →
Description: Companies in Healthcare Multiline Medical Device Solutions design, manufacture, and distribute broad portfolios of clinical equipment and consumables spanning diagnostics, monitoring, surgical, and therapy categories. Strategic buyers in this space provide end-to-end device ecosystems, unified procurement, and service coverage across care settings, helping providers standardize equipment, improve workflow reliability, and ensure regulatory compliance. Their diversified product lines support hospitals, clinics, and ambulatory centers with scalable options from capital equipment to single-use supplies.
Johnson & Johnson
- Type: N/A
- Employees: ●●●●●
- Description: Provider of pharmaceutical products and medical devices addressing immune disorders, cancer, neurological, infectious, cardiovascular and metabolic diseases, plus technologies for cardiovascular, orthopedic, neurovascular, general surgery and vision care; engaged in research, development, manufacturing and global sale of medicines and medical technologies to retailers, wholesalers, healthcare professionals and hospitals.
- Key Products:
- Pharmaceutical Therapeutics Portfolio: Treatments targeting immune disorders, cancer, neurological, infectious, cardiovascular and metabolic diseases, developed and manufactured for prescription use by healthcare professionals
- Cardiovascular & Orthopedic Medical Devices: Implantable devices and surgical instruments for cardiovascular interventions, orthopedic reconstruction and neurovascular care, enhancing surgical precision and patient outcomes
- General & Vision Surgery Technologies: Instruments and equipment supporting general surgery and vision care procedures, delivering advanced functionality that improves clinical efficiency and patient recovery
- Consumer Health Brands (Johnson’s
- Benadryl
- Listerine): Over-the-counter medicines and personal care lines offering baby care, allergy relief and oral hygiene, distributed through global retail and wholesale channels.
🔒
🔒
🔒
View all 27 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in PVD Treatment Medical Devices sector
3.1 - Buyout funds in the PVD Treatment Medical Devices sector
2.2 - Strategic buyer groups for PVD Treatment Medical Devices sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PVD Treatment Medical Devices companies
4.2 - Public trading comparable groups for PVD Treatment Medical Devices sector
Valuation benchmark group 1: Cardiovascular and Electrophysiology Device Manufacturers
15 companies
View group →
Description: Companies in this trading comparable group design, manufacture, and market cardiovascular and electrophysiology medical devices used in interventional and surgical procedures. Portfolios span implants and disposable tools with recurring procedure-driven demand. They are grouped as comparables due to similar regulatory pathways, hospital-based sales models, capital and consumable mix, clinical evidence requirements, and margin structures that set valuation benchmarks for public trading comparables in cardiac and vascular care.
Boston Scientific
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medical solutions, developing and manufacturing medical devices for interventional medical specialties including cardiology, oncology, endoscopy, and neuromodulation, aimed at improving patient health and transforming lives worldwide.
- Key Products:
- Cardiac Devices: Devices for diagnosing and treating heart conditions including stents, pacemakers, and defibrillators
- Oncology Solutions: Minimally invasive medical devices for diagnosing and treating various cancers
- Endoscopy Devices: Tools for diagnosing and treating gastrointestinal and pulmonary conditions
- Neuromodulation Devices: Electronic implantable technologies for managing chronic pain and neurological disorders
- Peripheral Intervention Devices: Technologies for treating peripheral artery and vein conditions.
🔒
🔒
🔒
View all 15 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →